Document 0021
 DOCN  M9580021
 TI    Gene-targeted inhibition of transactivation of human immunodeficiency
       virus type-1 (HIV-1)-LTR by antisense oligonucleotides.
 DT    9506
 AU    Demirhan I; Hasselmayer O; Hofmann D; Chandra A; Svinarchuk FP; Vlassov
       VV; Engels J; Chandra P; Laboratory of Molecular Biology, Frankfurt
       University School of; Medicine, FRG.
 SO    Virus Genes. 1995 Jan;9(2):113-9. Unique Identifier : AIDSLINE
       MED/95250303
 AB    We have used an in vitro approach to study the efficiency of antisense
       oligonucleotides in inhibiting LTR-(HIV-1)-directed CAT expression
       catalyzed by tat protein, the functional protein of the transactivator
       gene. We selected the target sequence localized near the 5' end of the
       tat mRNA. The following conclusions can be drawn from the data presented
       here: a) Antisense oligonucleotides modified by conjugation of
       cholesterol at the 3' end have a severalfold higher inhibitory response,
       b) inhibitory response is dependent on the mode of introducing
       oligonucleotides, and c) the inhibition by antisense oligonucleotides is
       sequence specific and directed towards the targeted region. This
       approach could be useful for targeting functional regions of regulatory
       gene products and designing gene-targeted inhibitors of virus
       replication.
 DE    Animal  Base Sequence  Cats/GENETICS  Cell Line  Gene Products,
       tat/GENETICS/METABOLISM  *Gene Targeting  Human  HIV Long Terminal
       Repeat/*GENETICS  HIV-1/GENETICS  Molecular Sequence Data
       Oligonucleotides, Antisense/*PHARMACOLOGY  Trans-Activation
       (Genetics)/*DRUG EFFECTS  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).